Pharsight

Drugs that contain Nintedanib Esylate

1. Ofev patents expiration

OFEV's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(a month ago)

US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(1 year, 5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7989474 BOEHRINGER INGELHEIM Use of Lck inhibitors for treatment of immunologic diseases
Apr, 2024

(14 days ago)

US10154990 BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases
Jan, 2026

(1 year, 8 months from now)

US6762180

(Pediatric)

BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Apr, 2026

(1 year, 11 months from now)

US10154990

(Pediatric)

BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases
Jul, 2026

(2 years from now)

US10105323 BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative
Jun, 2029

(5 years from now)

US9907756 BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Jun, 2029

(5 years from now)

US10105323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative
Dec, 2029

(5 years from now)

US9907756

(Pediatric)

BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-261) Sep 06, 2026
Pediatric Exclusivity(PED) Mar 06, 2027
New Indication(I-805) Sep 06, 2022
Orphan Drug Exclusivity(ODE) Oct 15, 2021
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
New Indication(I-825) Mar 09, 2023
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021

NCE-1 date: 06 March, 2026

Market Authorisation Date: 15 October, 2014

Treatment: Treatment of idiopathic pulmonary fibrosis (ipf); Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-...

Dosage: CAPSULE;ORAL

How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage

OFEV family patents

Family Patents